COYA Stock Forecast & Price Target

Coya Therapeutics has obtained FDA clearance for a Phase 2a study, demonstrating significant and sustained increases in regulatory T-cell function and numbers, which persisted over a 22-week treatment period without cognitive decline in patients with frontotemporal dementia. The company reported robust early and durable engagement of regulatory T cells and positive biomarker analyses, further validating its approach in neurodegenerative disorders. Additionally, Coya Therapeutics has achieved operational milestones through multiple IND approvals and the initiation of its ALSTARS Phase 2 trial, reinforcing its commitment to advancing innovative therapies in the clinical stage.

Coya Therapeutics currently faces significant challenges that contribute to a negative outlook, including the poor commercial uptake of COYA 302 and potential delays with other pipeline candidates. Additionally, the company encounters partnership risks, particularly related to its collaboration with DRL, which could hinder its operational effectiveness. Furthermore, there is a looming threat of medium-term equity dilution, compounded by the risk of clinical setbacks and the inability to progress COYA 302 into pivotal development stages.